Smaller companies set for third-quarter catalysts
The third quarter will see important data for Travere, Radius and Sio Gene, among other small developers.
Second-quarter catalysts for the smaller players
Key catalysts approach for Orphazyme, Gemini and Immutep.
Positive data Kalm Cara investors
Cara Therapeutics’ stock shot up 18% today on data derisking two key projects.
Upcoming events – Pivotal data for Galapagos and Cara
Galapagos will discover if filgotinib can hang on to its reputation as one of the safest Jak inhibitors in the industry, while Cara is itching for pivotal trial success…